📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: PhaseRx

1.1 - Company Overview

PhaseRx Logo

PhaseRx

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of delivery solutions for siRNA and other macromolecular therapeutics for the treatment of orphan diseases.

Products and services

🔒

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to PhaseRx

Editas Medicine Logo

Editas Medicine

HQ: United States Website
  • Description: Provider of clinical-stage genome editing medicines and a CRISPR gene editing platform, including Reni-cel for severe sickle cell disease and transfusion-dependent beta thalassemia (editing CD34+ cells at HBG1/HBG2 promoters), EDIT-101 for Leber congenital amaurosis 10 (repairing the IVS26 CEP290 allele), and ex vivo and in vivo gene editing medicines for ocular, blood diseases, and cancer.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Editas Medicine company profile →
SalioGen Logo

SalioGen

HQ: United States Website
  • Description: Provider of non-viral Gene Coding technology enabling precise integration of large or multiple whole genes without double-strand breaks or guide RNA, and of programs including SGT-1001 for Stargardt disease, one-time genetic medicines for cystic fibrosis, CAR-T cell engineering for cancer and autoimmune diseases with tissue-specific integration, and therapies for inherited retinal diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full SalioGen company profile →
Beam Therapeutics Logo

Beam Therapeutics

HQ: United States Website
  • Description: Provider of precision genetic medicines using base editing, including BEAM-101 for sickle cell disease; BEAM-201, an anti-CD7 CAR-T for relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma; and liver-targeting LNPs BEAM-301 and BEAM-302 to correct the R83C mutation in Glycogen Storage Disease Type 1a and the PiZ allele in severe Alpha-1 antitrypsin deficiency, plus base editing delivery technologies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Beam Therapeutics company profile →
Prevail Therapeutics Logo

Prevail Therapeutics

HQ: United States Website
  • Description: Provider of novel AAV9-based gene therapies for neurodegenerative diseases. Offerings include PR001, delivering a healthy GBA1 gene to correct lysosomal dysfunction in Parkinson's disease with GBA1 mutations and Type 1 Gaucher disease, and PR006, delivering a healthy GRN gene to raise progranulin for frontotemporal dementia.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Prevail Therapeutics company profile →
CRISPR Therapeutics Logo

CRISPR Therapeutics

HQ: United States Website
  • Description: Provider of a proprietary CRISPR/Cas9 gene-editing platform and therapies to treat serious diseases, including CASGEVY™ (exagamglogene autotemcel), approved in some countries for sickle cell disease and transfusion-dependent beta thalassemia; CTX112, an investigational allogeneic CD19 CAR T therapy; and ex vivo and in vivo gene-editing and cell therapy approaches using viral and non-viral delivery.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CRISPR Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for PhaseRx

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to PhaseRx

2.2 - Growth funds investing in similar companies to PhaseRx

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for PhaseRx

4.2 - Public trading comparable groups for PhaseRx

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to PhaseRx

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About PhaseRx

What does PhaseRx do?

PhaseRx is a provider of delivery solutions for siRNA and other macromolecular therapeutics for the treatment of orphan diseases.

Who are PhaseRx's competitors?

PhaseRx's competitors and similar companies include Editas Medicine, SalioGen, Beam Therapeutics, Prevail Therapeutics, and CRISPR Therapeutics.

Where is PhaseRx headquartered?

PhaseRx is headquartered in United States.

How many employees does PhaseRx have?

PhaseRx has 1,000 employees 🔒.

When was PhaseRx founded?

PhaseRx was founded in 2010 🔒.

What sector and industry vertical is PhaseRx in?

PhaseRx is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for PhaseRx

Who are the top strategic acquirers in PhaseRx's sector and industry

Top strategic M&A buyers and acquirers in PhaseRx's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for PhaseRx?

Top strategic M&A buyers groups and sectors for PhaseRx include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in PhaseRx's sector and industry vertical

Which are the top PE firms investing in PhaseRx's sector and industry vertical?

Top PE firms investing in PhaseRx's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in PhaseRx's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in PhaseRx's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in PhaseRx's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to PhaseRx include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in PhaseRx's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for PhaseRx?

The key public trading comparables and valuation benchmarks for PhaseRx include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for PhaseRx for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for PhaseRx with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in PhaseRx's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for PhaseRx with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in PhaseRx's' sector and industry vertical?

Access recent funding rounds and capital raises in PhaseRx's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for PhaseRx